RecruitingPhase 2NCT06840899

CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury

Cannabinoid Modulation for Neurogenic Lower Urinary Tract Dysfunction in Spinal Cord Injury


Sponsor

University of Wisconsin, Madison

Enrollment

20 participants

Start Date

Feb 13, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI). Participants will take Epidiolex (purified CBD) for 90 days


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • \>18 years of age
  • History of supra-sacral spinal cord injury of any mechanism
  • Urinary incontinence with ≥2 episodes of urinary incontinence per day (outside of spinal shock)
  • Willingness to participate in drug intervention trial
  • English-speaking (able to provide consent and complete questionnaires)

Exclusion Criteria4

  • History of intravesical Botox
  • Actively taking \>15 mg of Oxybutynin single dose or equivalent dose of alternative anticholinergic medication for bladder symptoms
  • Use of Cannabis (any form) outside of study as determined by urine drug screen after washout period of 1 month if prior Cannabis use reported
  • Thought or mood disorder aside from depression

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCBD

Twice daily 100mg cannabidiol (CBD)


Locations(1)

University of Wisconsin - Madison

Madison, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06840899


Related Trials